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BACKGROUND & AIMS: The combination of peginterferon and
ribavirin with telaprevir or boceprevir is the standard treat-
ment of hepatitis C virus (HCV) genotype 1 infection. However,
these drugs are not well tolerated because of their side effects
and suboptimal virologic responses. In a phase 2a, open-label
study, we examined the safety and efﬁcacy of an interferon-
free, ribavirin-free regimen of direct-acting antivirals,
comprising daclatasvir (an NS5A replication complex inhibitor),
asunaprevir (an NS3 protease inhibitor), and BMS-791325 (a
non-nucleoside NS5B inhibitor), in patients with chronic HCV
infection. METHODS:We analyzed data from 66 treatment-naive
patients with HCV genotype 1 infection without cirrhosis who
were assigned randomly to groups given daclatasvir (60 mg, once
daily), asunaprevir (200mg, twice daily), and BMS-791325 (75 or
150 mg, twice daily) for 12 or 24 weeks. The primary end point
was an HCV-RNA level less than 25 IU/mL at 12 weeks after
treatment (sustained virologic response at 12 weeks [SVR12]).
RESULTS: In 64 patients, HCV-RNA levels were less than 25
IU/mL by week 4 of treatment (including 48 of 49 patients with
HCV genotype 1a infection and 45 of 46 patients with the non-CC
interleukin 28B genotype). Sixty-one patients (92%) achieved
SVR12, based on a modiﬁed intention-to-treat analysis. Virologic
responses were similar between 12 and 24 weeks of treatment.
During the study, 2 patients experienced viral breakthrough and
1 patient relapsed. There were no grade 3–4 increases in levels
of alanine or aspartate aminotransferases or bilirubin; there
were no deaths or discontinuations resulting from serious
adverse events or adverse events related to the treatment
regimen. The most common adverse events were headache,
asthenia, and gastrointestinal symptoms. CONCLUSIONS: In a
phase 2a study, the all-oral, interferon-free, and ribavirin-free
regimen of daclatasvir, asunaprevir, and BMS-791325 was welltolerated and achieved high rates of SVR12 in patients with HCV
genotype 1 infection. Further studies of this regimen are war-
ranted. ClinicalTrials.gov, number NCT01455090.Keywords: Liver Disease; Therapy; DAA; Drug Combination.
Watch this article’s video abstract and others at http://tiny.cc/j026c.Scan the quick response (QR) code to the left
with your mobile device to watch this article’s
video abstract and others. Don’t have a QR code
reader? Get one by searching ‘QR Scanner’ in
your mobile device’s app store.he current standard of care for the treatment ofTpatients chronically infected with hepatitis C virus
(HCV) genotype (GT) 1 is a 3-drug regimen, with peginter-
feron alfa and ribavirin plus telaprevir or boceprevir. Sus-
tained virologic response (SVR) rates with 3-drug therapy
are approximately 70% in treatment-naive patients, a sig-
niﬁcant improvement over the SVR of approximately 40%
for peginterferon/ribavirin alone.1–4 Despite improvement
in SVR, these regimens are poorly tolerated. The most
common side effects of peginterferon alfa/ribavirin are ﬂu-
like symptoms, depression, and hematologic toxicity.5
Addition of boceprevir or telaprevir to peginterferon alfa/
ribavirin increases the severity of anemia and adds
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threatening.3,4 In addition, these regimens require 24 to 48
weeks of weekly injections of peginterferon, up to 3 pills
twice daily of ribavirin, and administration of 3 or 4 pills of
telaprevir or boceprevir with a meal 3 times a day. An
interferon-free, ribavirin-free regimen with improved
tolerability and less-frequent dosing for improved adher-
ence, while achieving high rates of SVR, is desirable.
Several antivirals with different mechanisms of action
that directly inhibit HCV replication are currently in clinical
development.6 Lok et al7 showed that SVR was possible
with an interferon-free, ribavirin-free regimen combining
multiple direct-acting antivirals, each having a different
mechanism of action. In this study, daclatasvir, an NS5A
replication complex inhibitor,8 was combined with asunap-
revir, an NS3 protease inhibitor,9 to treat patients with HCV
GT 1 who were null responders to prior treatment with
peginterferon/ribavirin.10 This dual combination achieved
SVR at 24 weeks after end of treatment (SVR24) in 36% of
the patients (2 of 9 patients with GT 1a and 2 of 2 patients
with GT 1b).7 In subsequent studies this dual regimen
achieved SVR24 of 83%–91% in HCV GT 1b null
responders,11–13 but a more potent regimen is required for
HCV GT 1a. Addition of ribavirin to this dual combination
did not improve response rates in GT 1a null responder
patients,11 thus it was hypothesized that addition of a
third direct-acting antiviral agent may enhance antiviral
potency.
The addition of the selective non-nucleoside polymerase
inhibitor, BMS-791325, to daclatasvir and asunaprevir ach-
ieves inhibition of 3 distinct viral targets that are respon-
sible for HCV replication. Potentially, this strategy would
increase the SVR rate and protect against the emergence of
viral resistance. Avoiding interferon and ribavirin also
would improve tolerability, perhaps increasing compliance,
resulting in more effective therapy. The study presented
here describes outcomes from 12 or 24 weeks of treatment
with an interferon-free, ribavirin-free combination of
daclatasvir, asunaprevir, and BMS-791325 in treatment-
naive patients with HCV GT 1 infection.Methods
Study Design
This open-label, randomized, phase 2a study recruited pa-
tients from 13 centers in the United States and France. Patients
were enrolled and completed treatment from November 17,
2011, to March 5, 2013. The study was approved by appro-
priate institutional review boards and/or independent ethics
committees, and was performed in accordance with the
Declaration of Helsinki and Good Clinical Practice as deﬁned by
the International Conference on Harmonization and ethical
principles of local regulatory requirements. All patients pro-
vided written informed consent. All authors had access to the
study data and reviewed and approved the ﬁnal manuscript.
Inclusion criteria were age 18–70 years, chronic HCV GT 1
infection with RNA level of 105 IU/mL or greater, no previous
HCV therapy (treatment-naive), and no evidence of cirrhosis (as
documented by markers of cirrhosis, FibroTest [BioPredictive,Paris, France] score 0.72 and aspartate amino-
transferase:platelet ratio 2, or liver biopsy). Patients with a
FibroTest or aspartate aminotransferase:platelet ratio score
exceeding the threshold for study inclusion were required to
have a liver biopsy documenting the absence of cirrhosis. MET-
AVIR category for each patient was derived from the FibroTest
result based on the conversion on the manufacturer’s website.
Exclusion criteria included an alanine aminotransferase level
that was 5 or more the upper limit of normal, total bilirubin
level of 2 mg/dL or greater, direct bilirubin level greater than the
upper limit of normal, international normalized ratio of 1.7 or
greater, albumin level of 3.2 g/dL or less, hemoglobin level less
than 11 g/dL for women and less than 12 g/dL for men, absolute
neutrophil count less than 1.5  109 cells/L (or <1.2  109
cells/L for African American individuals), platelet count less than
90  109 cells/L, creatinine clearance less than 50 mL/min, and
ineligibility for peginterferon alfa 2a or ribavirin if needed for
treatment intensiﬁcation (see later). Women of child-bearing
potential were required to use at least 2 contraception methods.
All randomized patients received daclatasvir (60 mg,
orally, once daily), asunaprevir (200 mg, orally, twice daily),
and BMS-791325 orally at either 75 or 150 mg twice daily. The
dose selection of BMS-791325 was based on phase 1 antiviral
activity and safety. Initially, eligible patients were assigned
randomly to group 1 (BMS-791325 75 mg twice daily for 24
weeks) or group 2 (BMS-791325 75 mg twice daily for 12
weeks) using a computer-generated randomization scheme.
After 4 weeks of observation, a second cohort was assigned
randomly to group 3 (BMS-791325 150 mg twice daily for 24
weeks) or group 4 (BMS-791325 150 mg twice daily for 12
weeks). Patients were stratiﬁed by genotype 1a/1b, with 1b
patient enrollment targeted between 25% and 38% or less of
the total number of patients in each group. The primary end
point was an HCV-RNA level less than 25 IU/mL at SVR12.
Other end points included analysis of HCV RNA at various
time points during and after treatment, rates of viral break-
through and relapse, and assessment of safety and tolerability.
In the event of viral breakthrough (deﬁned as conﬁrmed in-
crease in HCV-RNA level 1 log10 from nadir or conﬁrmed HCV
RNA level 25 IU/mL on or after week 8), patients were eligible
to receive treatment intensiﬁcation, deﬁned as peginterferon
alfa-2a (180 mg subcutaneously, once weekly) and ribavirin
(1000 mg orally per day if patient weighed <75 kg, or 1200 mg
orally per day if patient weighed >75 kg) in addition to
continuation of the direct-acting antivirals for up to an addi-
tional 48 weeks.
Laboratory Assessment
Blood samples were drawn at baseline, days 1–7, days 9, 11,
14, 21, 28, every week through week 8, then every 2 weeks
until the end of treatment, and post-treatment weeks 4, 12, 24,
36, and 48. HCV-RNA level was determined at a central labo-
ratory using the COBAS TaqMan v2 assay (Roche Molecular
Diagnostics, Pleasanton, CA), with a lower limit of quantitation
of 25 IU/mL and a lower limit of detection of approximately 10
IU/mL. HCV genotypes were determined by polymerase chain
reaction ampliﬁcation and sequencing using the VERSANT HCV
Ampliﬁcation2.0Kit (LiPA) (Siemens,Munich, Germany). Thehost
interleukin (IL)28B genotype (rs12979860 single-nucleotide
polymorphism) was determined by Monogram Biosciences
(South San Francisco, CA) using a real-time polymerase chain
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morphisms in HCV NS3, NS5A, and NS5B associated with drug
resistance using population sequencing (sensitivity,z20%).
Safety Assessments
Safety and tolerability were measured by serious adverse
events, treatment-emergent adverse events, discontinuations
owing to adverse events, severity grade 3/4 adverse events, and
severity grade 3/4 laboratory abnormalities. Vital sign and
electrocardiographic measurements, physical examinations, and
clinical laboratory results were assessed throughout the study.
Statistical Analysis
Binary antiviral activity end points were assessed using
modiﬁed intent-to-treat methodology. Patients prescribed a
different treatment as assigned for the whole treatment dura-
tion were analyzed based on actual treatment (as treated). The
numerator was based on treated patients meeting response
criteria (deﬁned as an HCV-RNA level <25 IU/mL; patients
with missing HCV-RNA values were considered failures for that
visit; however, failure owing to a missed value does not carry
forward, in that, the patient can return later and be counted in
future analyses of sustained response). The denominator was
based on all treated patients.
Results
Disposition, Demographics, and
Baseline Characteristics
Sixty-six patients were randomized. In addition to dacla-
tasvir and asunaprevir, patients in groups 1 (N ¼ 16) and 2
(N¼ 16) received BMS-791325 75mg twice daily for 24 or 12
weeks, respectively, and patients in groups 3 (N ¼ 16) and 4
(N¼18) receivedBMS-791325150mg twicedaily for 24or12
weeks, respectively. In group 1, 2 patients discontinued
treatment beforeweek24, 1 patientwithdrewconsent atweek
9, and the other patient was discontinued at week 14 by the
investigator because of inability to comply with study pro-
cedures. In groups 2 and 3, 1 patient discontinued treatment at
week 11 because of poor compliance and 1 patient voluntarily
discontinued treatment atweek18 of the 24-week regimen for
reasons unrelated to the study. All group 4 patients (N ¼ 18)
completed the study. All groups were similar in age, race, and
baselineHCV-RNA viral load (Table 1). Seventy-four percent of
all patients were infected with HCV GT 1a, 70% of all patients
had IL28B non-CC genotype, andmore than 50%of all patients
had FibroTest-derived METAVIR scores of F2 or greater; pa-
tients with FibroTest scores suggestive of cirrhosis (>0.72)
were enrolled based on biopsy results showing an absence of
cirrhosis (Table 1). Eighteen percent of patients were African
American (Table 1).
Virologic Response
Groups 1 and 2, BMS-791325 75 mg twice
daily. After treatment initiation, HCV-RNA levels rapidly
decreased in both groups (Figure 1A and B). By week 4, all
patients (N ¼ 32) had achieved an HCV-RNA level less than
25 IU/mL and 97% (31 of 32) maintained an HCV-RNA levelless than 25 IU/mL through the end of treatment. One pa-
tient (group 1) had an HCV-RNA level of 118 IU/mL at the
last on-treatment visit but had an HCV-RNA level less than
25 IU/mL at 2, 4, and 12 weeks after treatment, suggesting a
possible laboratory error. By using the modiﬁed intent-to-
treat analysis (Table 2), 94% (30 of 32) of patients ach-
ieved SVR4 and SVR12. Ninety-one percent (29 of 32) of
patients achieved SVR24 and no patient experienced viral
breakthrough or post-treatment relapse.
Two patients missed their post-treatment week 4 and 12
visits and were counted as failures at these time points
(Table 2): 1 patient (group 1) withdrew consent but showed
undetectable HCV-RNA levels at treatment discontinuation
(on-treatment week 9), and 1 patient (group 2) missed SVR4
and SVR12 but achieved SVR24. Two patients, 1 patient from
each group, missed post-treatment week 24 visits but both
had achieved SVR4 and SVR12.
Groups 3 and 4, BMS-791325 150 mg twice
daily. After treatment initiation, HCV-RNA levels also
rapidly decreased in both groups (Figure 1C and D). By
week 4, all patients in group 3 (N ¼ 16) achieved HCV-RNA
levels less than 25 IU/mL and 94% (15 of 16) maintained
HCV-RNA levels less than 25 IU/mL through the end of
treatment. All but 2 patients in group 4 achieved an HCV-
RNA level less than 25 IU/mL at week 4: 1 patient had an
unconﬁrmed HCV-RNA level of 43 IU/mL and another pa-
tient missed the week 4 visit, but both achieved SVR12
and SVR24. Ninety-four percent of patients (32 of 34)
receiving BMS-791325 150 mg achieved an HCV-RNA level
less than 25 IU/mL at the last on-treatment visit. By using
modiﬁed intent-to-treat analysis (Table 2), 91% (31 of 34)
of patients receiving BMS-791325 150 mg achieved SVR4
and SVR12.
Three patients overall experienced virologic failure: 1
patient each in groups 3 and 4 experienced viral break-
through, and 1 patient in group 4 experienced relapse at
follow-up week 4. The patient in group 3 with viral break-
through was a 61-year-old black woman, randomized as
GT 1b, however, further sequencing suggested a GT1 non-1a
or 1b subtype analysis was ongoing. The patient further
showed IL28BTTgenotype, a FibroTest score of 0.62 (derived
METAVIR F3), and a baseline HCV-RNA level of 5.1 log10 IU/
mL. The patient achieved an HCV-RNA level less than 25 IU/
mL at week 3 and experienced viral breakthrough at week 6.
The group 4 patient was a 32-year-old white man with GT 1a,
IL28B TT genotype, FibroTest score of 0.11 (derived META-
VIR F0), and a baseline HCV-RNA level of 7.1 log10 IU/mL. The
patient achieved an HCV-RNA level of approximately 10 IU/
mL (undetectable) on week 4 and experienced viral break-
through at week 8. Both patients intensiﬁed treatment by
adding peginterferon alfa/ribavirin to the direct-acting anti-
virals. Sixteen weeks after starting treatment intensiﬁcation,
the group 3 patient discontinued all treatment because of a
serious adverse event (cerebral vasoconstriction related to
peginterferon alfa/ribavirin) and subsequently relapsed. The
patient from group 4 achieved an HCV-RNA level less than 25
IU/mL 6 weeks after the addition of peginterferon alfa/
ribavirin, and in preliminary data has achieved SVR4. One
patient (group 4) relapsed between the end of treatment and
Table 1.Demographics and Baseline Disease Characteristics
Group 1 2 3 4 Total
BMS-791325 dose, mg 75 75 150 150
Treatment duration, wk 24 12 24 12
N 16 16 16 18 66
Median age, y (range) 49 (44–61) 47 (24–67) 55 (25–67) 49 (29–68) 50 (24–68)
Male, n (%) 10 (63) 7 (44) 9 (56) 13 (72) 39 (59)
Race, n (%)
White 11 (69) 13 (81) 12 (75) 16 (89) 52 (79)
African American 5 (31) 3 (19) 3 (19) 1 (6) 12 (18)
Asian other 0 0 1 ( 6) 1 (6) 2 (3)
Body mass index, n (%)
<25, kg/m2 6 (38) 4 (25) 7 (44) 7 (39) 24 (36)
25 to <30, kg/m2 6 (38) 5 (31) 9 (56) 7 (39) 27 (41)
30, kg/m2 4 (25) 7 (44) 0 4 (22) 15 (23)
HCV-RNA level
Mean log10 IU/mL (SD) 6.3 (0.55) 6.2 (0.76) 6.4 (0.67) 6.3 (0.63) 6.3 (0.65)
Distribution, n (%)
<800,000 4 (25) 6 (38) 3 (19) 4 (22) 17 (26)
800,000 12 (75) 10 (63) 13 (81) 14 (78) 49 (74)
HCV genotype, n (%)
1a 12 (75) 12 (75) 12 (75) 13 (72) 49 (74)
1b 4 (25) 4 (25) 4 (25) 5 (28) 17 (26)
IL28B genotype (rs12979860), n (%)
CC 4 (25) 5 (31) 5 (31) 6 (33) 20 (30)
CT 10 (63) 11 (69) 7 (44) 10 (56) 38 (58)
TT 2 (13) 0 4 (25) 2 (11) 8 (12)
FibroTest score, median (range)a 0.51 (0.09–0.78) 0.27 (0.03–0.91) 0.38 (0.05–0.66) 0.42 (0.06–0.80) 0.36 (0.03–0.91)
METAVIR scores derived from FibroTestb
F0–F1 5 (31) 11 (69) 5 (31) 7 (39) 28 (42)
F2–F3 10 (63) 4 (25) 10 (63) 9 (50) 33 (50)
>F3c 1 (6) 1 (6) 0 2 (11) 4 (6)
Not reported 0 0 1 (6)d 0 1 (2)d
NOTE. Treatment consisted of daclatasvir (60 mg, orally, once daily), asunaprevir (200 mg, orally, twice daily), and BMS-
791325 (75 or 150 mg orally, twice daily) for 24 or 12 weeks.
aData calculated at ICON Central Laboratories.
bMETAVIR category for each patient was derived from the FibroTest (BioPredictive) score, conversion was based on the
manufacturer’s website. F0–F1, METAVIR categories F0, F0–F1, and F1; F2–F3, METAVIR categories F1–F2, F2, and F3; >F3,
METAVIR categories F3–F4 and F4.
cPatients with a FibroTest score exceeding the threshold for inclusion in the study (0.72 and an aspartate amino-
transferase:platelet ratio 2) were required to have a liver biopsy to show the absence of cirrhosis.
dOne patient was not able to have the FibroTest result calculated and instead had a biopsy performed to exclude cirrhosis.
February 2014 Daclatasvir, Asunaprevir, BMS-791325 for HCV 423
CL
IN
IC
AL
LI
VE
R
post-treatment week 4. This patient was a 61-year-old white
man, with GT 1a, IL28B CT genotype, FibroTest score of 0.66
(derived METAVIR F3), and baseline HCV-RNA level of 6.8
log10 IU/mL. The patient achieved an HCV-RNA level of
approximately 10 IU/mL (undetectable) at week 3, which
continued through the end of treatment. Resistance-
associated variants detected at baseline and at the time of
virologic failure are summarized for the 3 patients who
experienced virologic failure in Supplementary Table 1.
Sustained virologic response by HCV subtype and IL28B
host genotype are presented in Table 3.Resistance
Polymorphisms at amino acid positions associated with
resistance to one or more of the direct-acting antivirals weredetected at baseline (Table 4).14–17 One patient from group
4 infected with HCV GT 1a had NS5A-L31M at baseline and
experienced viral breakthrough at week 8; this poly-
morphism has been shown to yield a 250-fold change in the
in vitro median effective concentration (EC50) of dacla-
tasvir.15 NS5A-Q30R-L31M, NS3-R155K, and NS5B-P495L
were detected at viral breakthrough. Another HCV GT
1a–infected patient (group 4) who experienced a relapse
4 weeks after treatment had NS5A-H58P and NS3-V36M
polymorphisms at baseline, and NS5A-M28A-Q30R-H58P,
NS3-V36M-R155K, and NS5B-P495L at post-treatment
weeks 4 and 12. Sequence polymorphism data at baseline
and virologic failure for the patient in group 3 who expe-
rienced viral breakthrough at week 6 currently are un-
available owing to poor sequence ampliﬁcation despite
multiple methodologies.
Figure 1. (A–D) HCV-RNA levels over time for individual patients in groups 1–4. Patients were treated with daclatasvir (60 mg,
orally, once daily), asunaprevir (200 mg, orally, twice daily), plus (A) BMS-791325 75 mg twice daily for 24 weeks, (B) BMS-
791325 75 mg twice daily for 12 weeks, (C) BMS-791325 150 mg twice daily for 24 weeks, (D) or BMS-791325 150 mg
twice daily for 12 weeks. N equals 16 each for groups 1 through 3, and 18 for group 4. PT, post-treatment.
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One serious adverse event of ureteral calculus (group 2)
occurred on treatment day 24 and was considered by the
investigator to be unrelated to study therapy (Table 5). No
deaths or adverse events leading to discontinuation
occurred during the study on the direct-acting antiviral
regimen alone (Table 5). One patient (group 2) had a grade
3 headache that resolved after 7 days with continuation of
study treatment. The most common adverse events (10%
of patients) included headache, asthenia, diarrhea, nausea,
and abdominal pain, all were mild or moderate in intensity.
One patient (group 2) experienced grade 4 lymphopenia on
day 14 concomitant with inﬂuenza infection, which started
on day 12 (Table 5). All subsequent lymphocyte results
were within the normal range. During treatment intensiﬁ-
cation, 1 patient (group 3) experienced grade 3 neutropenia
and a serious adverse event of cerebral vasoconstriction
(grade 3) leading to treatment discontinuation, both
considered by the investigator to be related to peginterferon
alfa/ribavirin and not to the direct-acting antiviral regimen.
There were no grade 3–4 laboratory events on the
direct-acting antiviral regimen alone speciﬁc to alanineaminotransferase, aspartate aminotransferase, bilirubin, he-
moglobin, leukocytes, absolute neutrophil count, or platelet
count. Importantly, no clinically meaningful change in he-
moglobin values were observed during treatment, although
modestmeanhemoglobin changes of -0.42 to -0.92 g/dLwere
observed up to treatment week 4 (Supplementary Table 2).
These decreases were not dose-dependent and improved
during the course of treatment, thus likely reﬂecting the
intense safety, efﬁcacy, and pharmacokinetic phlebotomy
requirements during the ﬁrst 28 days of this study.Discussion
Currently approved treatment regimens for HCV GT
1–infected patients include a protease inhibitor combined
with peginterferon/ribavirin and have modest antiviral ac-
tivity, poor tolerability, and long treatment durations.18–20
For these reasons, interferon-free treatment regimens with
multiple direct-acting antivirals are in clinical development.
Two direct-acting antivirals, daclatasvir and asunaprevir,
without interferon or ribavirin, were able to achieve high
SVR rates in GT 1b–infected patients, but a high rate of viral
Table 2.Virologic Response During and After Treatment
Group 1 2 3 4
BMS-791325 dose, mg 75 75 150 150
Treatment duration, wk 24 12 24 12
N 16 16 16 18
% < LOQ on-treatment
Week 4 16/16 (100) 16/16 (100) 16/16 (100) 16/18 (89)a
End of treatment
(includes early discontinuations)
15/16 (94)b 16/16 (100) 15/16 (94) 17/18 (94)
Post-treatment SVRs
Week 4 15/16 (94)c 15/16 (94)d 15/16 (94) 16/18 (89)
Week 12 15/16 (94)c 15/16 (94)d 15/16 (94) 16/18 (89)
Week 24 14/16 (88)d,e 15/16 (94)f In progress In progress
Virologic failure
Viral breakthrough 0/16 0/16 1/16 (6) 1/18 (6)
Viral relapse 0/16 0/16 0/16 1/18 (6)
NOTE. Data are shown as n (%). Virologic response was deﬁned as an HCV-RNA level <25 IU/mL. The analyses were per-
formed using modiﬁed intent-to-treat population (all patients who received at least 1 dose of study medication). Treatment
consisted of daclatasvir (60 mg, orally, once daily), asunaprevir (200 mg, orally, twice daily), and BMS-791325 (75 or 150 mg
orally, twice daily) for 24 or 12 weeks.
LOQ, limit of quantitation.
aIncludes 1 patient with unconﬁrmed HCV-RNA level of 43 IU/mL and 1 patient who missed a visit.
bIncludes 1 patient with an HCV-RNA level of 118 (IU/mL) at last on-treatment visit but <25 IU/mL at 2, 4, and 12 weeks post-
treatment.
cIncludes 1 patient who withdrew consent before week 12.
dIncludes 1 patient who achieved SVR24 but missed the SVR4 and SVR12 visits.
eIncludes a patient who achieved SVR4 and SVR12 but missed the week 24 visit.
fIncludes a patient who achieved SVR4 and SVR12 but missed the week 24 visit.
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1a.7,11–13 This ﬁnding is consistent with modeling that
predicts successful interferon-free, direct-acting antiviral
combinations must impose a high genetic barrier to 4 or
more HCV variants to prevent emergence of resistance.21Table 3.Virologic Response by HCV and Host IL28B Genotype
BMS-791325 dose, mg
HCV genotype, n/N (%)
1a 1
75 150 75
Week 4 24/24 (100) 24/25 (96)a 8/8 (100)
End of treatment 23/24 (96)c 24/25 (96)d 8/8 (100)
SVR4 23/24 (96)
e 23/25 (92)d,f 7/8 (88)g
SVR12 23/24 (96)
e 23/25 (92)d,f 7/8 (88)g
SVR24 21/24 (88)
e,h 8/8 (100)
NOTE. Virologic response was deﬁned as an HCV-RNA level
intention-to-treat population (all patients who received at least 1
(60 mg, orally, once daily), asunaprevir (200 mg, orally, twice d
indicated) for 24 or 12 weeks.
aIncludes 1 patient with an unconﬁrmed HCV-RNA level of 43 I
bIncludes 1 patient who missed a visit.
cIncludes 1 patient with an HCV-RNA level of 118 IU/mL at the la
and 12 weeks after treatment.
dViral breakthrough.
eIncludes 1 patient who withdrew consent before week 12.
fPatient relapsed.
gIncludes 1 patient who achieved SVR24 but missed the SVR4
hIncludes 2 patients who achieved SVR4 and SVR12 but missedTwo clinical paradigms have emerged to enhance the ge-
netic barrier of interferon-free regimens. First, treatment
with a combination of 2 direct-acting antivirals, including a
nucleotide polymerase inhibitor with a high barrier to viral
resistance such as sofosbuvir, combined with a direct-actingIL28B genotype, n/N (%)
b CC Non-CC
150 75 150 75 150
8/9 (89)b 9/9 (100) 10/11 (91)a 23/23 (100) 22/23 (96)b
8/9 (89)d 9/9 (100) 11/11 (100) 22/23 (96)c 21/23 (91)d
8/9 (89)d 9/9 (100) 11/11 (100) 21/23 (91)e,g 20/23 (87)d,f
8/9 (89) 9/9 (100) 6/6 (100) 21/23 (91)e,g 10/12 (83) d,f
9/9 (100) 20/23 (87)e,h
of <25 IU/mL. The analyses were performed in a modiﬁed
dose of study medication). Treatment consisted of daclatasvir
aily), and BMS-791325 (75 or 150 mg orally, twice daily, as
U/mL.
st on-treatment visit but an HCV-RNA level <25 IU/mL at 2, 4,
and SVR12 visits.
the SVR24 visit.
Table 4.Polymorphisms Observed at Baseline Known to
Decrease Susceptibility to Daclatasvir, Asunaprevir,
or BMS-791325
Protein Genotype Polymorphisms Number of patients
NS3 1a V36M 2
1a V55A/I 3
1a Q80K 12
NS5A 1a L31M 2
1b L31M 1
1b Y93H 2
NS5B 1a L392I 1
1a A421V 11
1b V499A 5
NOTE. Some polymorphisms were detected as minor variants
or as the only variant at that position by population
sequencing. NS5A and NS5B polymorphisms conferred 2-
fold loss in potency to daclatasvir and BMS-791325 in vitro,
respectively. No polymorphisms were identiﬁed that
conferred 3-fold loss in potency to asunaprevir in vitro.
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LIVERantiviral with a different mechanism of action with high
potency such as the NS5A inhibitor daclatasvir or the NS3
protease inhibitor simeprevir, can achieve sustained
response without viral breakthrough.22,23 An alternative
strategy involves combining 2 or more non-nucleotide
direct-acting antivirals with or without ribavirin to improve
the genetic barrier to resistance.24–27 An interferon-free
combination of 3 direct-acting antivirals (an NS5B non-
nucleoside inhibitor, a ritonavir-boosted protease inhibitor,
and an NS5A inhibitor) plus ribavirin showed high SVR rates,
but treatment success was reduced when ribavirin or any
single direct-acting antiviral was omitted.27 In this study,
combining 3 direct-acting antivirals without interferon or
ribavirin showed a high SVR rate after 12 weeks of treatment
in HCV GT 1–infected, treatment-naive patients.Table 5.Safety Through the End of Treatment
Group
BMS-791325 dose, mg
Treatment duration, wk
N
Serious adverse events
Adverse events leading to discontinuation
Grade 3–4 adverse events
Grade 3–4 laboratory abnormalities
Adverse events in >10% of patients in combined treatment groups dur
Headache
Asthenia
Diarrhea
Nausea
Abdominal pain
Abdominal pain, upper
NOTE. Data are n (%). Treatment consisted of daclatasvir (60 m
and BMS-791325 (75 or 150 mg orally, twice daily) for 24 or 12
aUreteral calculus, considered by investigator to be unrelated t
bGrade 3 headache, resolved after 7 days with continued study
cLymphopenia at a single study visit concomitant with inﬂuenzaThis all-oral, interferon-free, ribavirin-free treatment
consisting of daclatasvir, asunaprevir, and BMS-791325 75
or 150 mg twice daily achieved up to 94% SVR12 after 24 or
12 weeks of treatment. Sustained response was achieved in
both HCV GT 1a–infected and HCV GT 1b–infected patients,
including patients with reduced interferon responsiveness
predicted by IL28B non-CC genotypes. No viral break-
through or relapse was observed in patients treated with
the 75 mg twice-daily dose of BMS-791325. There was
100% concordance between SVR4 and subsequent SVR time
points in all patients with available data.
An important aspect to this study is that SVR was ach-
ieved without inclusion of ribavirin. Ribavirin contributes to
anemia and it is teratogenic; thus, effective treatments
without ribavirin are desirable. This interferon- and
ribavirin-free regimen did not alter hemoglobin levels in a
clinically meaningfully manner as evidenced by no grade 1
or higher hemoglobin reductions and no adverse events of
anemia. The mechanism of action of ribavirin is not clear,
and its contribution to clinical efﬁcacy varies by regimen.
Ribavirin clearly improves SVR rates in interferon-based
therapies, including telaprevir-based regimens.28 Among
interferon-free regimens, the beneﬁt of ribavirin remains
unclear. The combination of the ritonavir-boosted protease
inhibitor ABT-450, the NS5B non-nucleoside inhibitor ABT-
333, and the NS5A inhibitor ABT-267 with or without
ribavirin showed lower SVR rates without ribavirin.27
However, the combination of daclatasvir and sofosbuvir
did not require ribavirin to achieve high SVR rates in pa-
tients with unfavorable characteristics, including HCV
genotypes 1a and 3, and host IL28B non-CC genotypes.22
The regimen presented here provides additional evidence
that combinations of potent direct-acting antivirals do not
always require ribavirin to achieve a sustained response.
This study also assessed the impact of treatment duration
on SVR and the regimen showed efﬁcacywith only 12weeks of1 2 3 4 Total
75 75 150 150
24 12 24 12
16 16 16 18 66
0 1 (6.3)a 0 0 1 (1.5)
0 0 0 0 0
0 1 (6.3)b 0 0 1 (1.5)
0 1 (6.3)c 0 0 1 (1.5)
ing treatment
4 (25.0) 6 (37.5) 4 (25.0) 4 (22.2) 18 (27.3)
2 (12.5) 3 (18.8) 2 (12.5) 4 (22.2) 11 (16.7)
2 (12.5) 6 (37.5) 2 (12.5) 1 (5.6) 11 (16.7)
1 (6.3) 2 (12.5) 2 (12.5) 4 (22.2) 9 (13.6)
0 0 3 (18.8) 4 (22.2) 7 (10.6)
1 (6.3) 1 (6.3) 3 (18.8) 2 (11.1) 7 (10.6)
g, orally, once daily), asunaprevir (200 mg, orally, twice daily)
weeks.
o study therapy.
treatment.
.
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Rtreatment. This therapeutic duration is consistent with publi-
cation of viral kinetic modeling data suggesting 10 weeks of
treatment with a potent antiviral regimen may be needed to
clear infected hepatocytes.29 In contrast, current treatment for
GT 1-infected patients includes peginterferon, ribavirin, and
the NS3 protease inhibitors telaprevir or boceprevir for up to
48 weeks.30 Shorter treatment durations are preferable
because they may improve patient compliance. In this study,
treatment periods of both 12 and 24 weeks yielded high SVR
rates, suggesting no advantage for extending treatment dura-
tion to 24 weeks. The study using ABT-450 boosted with
ritonavir, ABT-333, ABT-267, and ribavirin in GT 1 treatment-
naive patients also showed high rates of SVR with only 12
weeks of therapy.27 Similarly, regimens including sofosbuvir
and daclatasvir with or without ribavirin also showed high
rates of SVR with 12 weeks of treatment.22,31
In our study, virologic failure was uncommon and
observed in only 3 patients in the 150 mg twice-daily dosing
groups: 2 patientswith viral breakthrough, and 1 patientwith
virologic relapse. The reasons for treatment failure in these
patients remain unclear but could include baseline virus
polymorphisms, host immune status, and/or reduced drug
exposure or adherence. Two of these patients were infected
with HCV GT 1a. One patient had a pre-existing NS5A variant
with increased resistance to daclatasvir (L31M, 250-fold
change in the EC50 of daclatasvir in vitro). The second pa-
tient had baseline resistance-associated polymorphisms to
daclatasvir and asunaprevir (NS5A-H58P and NS3-V36M,
respectively), which alone do not appear to alter the EC50
value of the direct-acting antivirals in vitro. It is possible that
these variants acted in a compensatory manner by enhancing
the ﬁtness of the emergent variants. The emergent linked
NS5A substitution M28A-Q30R confers high-level resistance
to daclatasvir in vitro (>200,000-fold resistance). NS3-V36M
enhances resistance by approximately 3-fold against asu-
naprevir when combined with NS3-R155K in vitro. The
HCV-RNA sequences of the third patient with HCV GT 1b re-
ported at screening have not been ampliﬁed successfully
despite numerous attempts, thus the HCV GT remains un-
conﬁrmed and the presence of baseline and emergent vari-
ants is unknown. The relationship between pre-existing
polymorphisms and treatment failure of interferon-free reg-
imens is unclear because patients in this and other studies
with similar ﬁndings have achieved a sustained response.
Thus, larger studies are needed to clarify the impact of pre-
existing polymorphisms on efﬁcacy.13,22,32,33 The role of
IL28B host genotype in virologic failure in patients treated
with other interferon-free regimens also is unclear. All 3 pa-
tients with virologic failure in this study were IL28B non-CC,
but this may be a reﬂection of most patients enrolled in the
study (70%) being IL28B non-CC. Recent studies have
conﬁrmed that interferon-free regimens achieve high SVR
rates in patients with IL28B non-CC genotype, and IL28B non-
CC genotype did not predict failure.7,11–13,22,25 Finally, pre-
liminary pharmacokinetic assessments of patients in this
study do not suggest any clinically relevant drug–drug in-
teractions among the 3 direct-acting antivirals in this com-
bination, and the pharmacokinetic proﬁles of daclatasvir,
asunaprevir, and BMS-791325 did not differ markedly in the3 patients with virologic failure as compared with the
remainder of the patients in the study.34 The observation that
virologic failure occurred only among patients receiving
BMS-791325 150 mg may reﬂect the small sample size
studied thus far and not necessarily represent a true differ-
ence in efﬁcacy between BMS-791325 doses. Both doses
remain under evaluation in the ongoing phase 2b study
expansion.
In summary, the combination of daclatasvir, asunaprevir,
and BMS-791325 generally was well tolerated and may
represent a signiﬁcant improvement over current treatments.
SVR rates generally exceeded 90%, and the most common
adverse events were headache, asthenia, and gastrointestinal
complaints (diarrhea, nausea, and abdominal pain); and did
not lead to treatment discontinuation. Furthermore, no
serious adverse events related to these direct-acting antivi-
ralswere observed and only one grade 3 or 4 laboratory value
was documented while on direct-acting antiviral–only ther-
apy (reversible lymphopenia during inﬂuenza infection).
These adverse events and side effects were minor in com-
parison with the reported rates and severity of adverse
events associated with peginterferon, ribavirin, and either
telaprevir or boceprevir.35,36 Indeed, during treatment
intensiﬁcation with peginterferon alfa/ribavirin, 1 patient
experienced a serious adverse event of cerebral vasocon-
striction (cerebrovascular disorders are observed with the
use of peginterferon alfa-2a [Pegasys, Genentech - Hoffmann-
La Roche, South San Francisco, CA] per the package insert).37
This tolerability proﬁle is also similar to that observed in
studies of asunaprevir and daclatasvir given as dual therapy
for HCV GT 1b,7,11–13 suggesting that the addition of BMS-
791325 does not add to the adverse event proﬁle of this
regimen.
We conclude that this all-oral, interferon-free, ribavirin-
free treatment of daclatasvir, asunaprevir, and BMS-791325
is a promising therapy for chronic hepatitis C that warrants
additional investigation. Limitations of this pilot study
included small patient numbers, restrictive inclusion and
exclusion criteria, and selection of noncirrhotic, treatment-
naive HCV GT 1–infected patients for initial study. This study
has been expanded to examine both doses of BMS-791325 in
additional HCV GT 1 treatment-naive patients, GT 1 null re-
sponders to prior peginterferon/ribavirin treatment, patients
with cirrhosis, and patients infected with HCV GT 4.Supplementary Material
Note: To access the supplementary material accompanying
this article, visit the online version of Gastroenterology at
www.gastrojournal.org, and at http://dx.doi.org/10.1053/
j.gastro.2013.10.057.References
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